The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.
Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
Amikacin sulfate is a semi-synthetic aminoglycosideantibiotic derived from kanamycin. It is C22H43N5O13•2H2SO4, D-streptamine, 0-3-amino-3-deoxy-α-D-glucopyranosyl-(1→6)-0-[6-amino-6- deoxy-α-D-glucopyranosyl-(1→4)]-N1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (S)-, sulfate (1:2) (salt).The dosage form supplied is a sterile, colorless solution.The solution contains, in addition to amikacin sulfate, USP, 2.5% sodium citrate, USP with pH adjusted to 4.5 with sulfuric acid and 0.66% sodium bisulfite added. The multi-dose 12 gram–48 mL vial contains 0.01% benzethonium chloride, USP as a preservative.
Antibacterial ActivityThe effectiveness of AMIGLYDE-V (amikacin sulfate injection) in infections caused by Escherichia coli, Pseudomonas sp and Klebsiella sp has been demonstrated clinically in the horse. In addition, the following microorganisms have been shown to be susceptible to amikacin in vitro1, although the clinical significance of this action has not been demonstrated in animals:• Enterobacter sp• Proteus mirabilis• Proteus sp (indole positive)• Serratia marcescens• Salmonella sp• Shigella sp• Providencia sp• Citrobacter freundii• Listeria monocytogenesureus (both penicillin-resistant and penicillin-sensitive)The aminoglycoside antibiotics in general have limitedactivity against gram-positive pathogens, although Staphylococcus aureus and Listeria monocytogenes are susceptible to amikacin as noted above.Amikacin has been shown to be effective against many aminoglycoside-resistant strains due to itsability to resist degradation by aminoglycosideinactivating enzymes known to affect gentamicin,tobramycin and kanamycin2.
Endometrial Tissue ConcentrationsComparisons of amikacin activity in endometrial biopsy tissue following intrauterine infusion with that following intramuscular injection of AMIGLYDE-V in mares demonstrate superior endometrial tissue concentrations when the drug is administered bythe intrauterine route.Intrauterine infusion of 2 grams AMIGLYDE-V daily for three consecutive days in mares results in peak concentrations typically exceeding 40 mcg/g of endometrial biopsy tissue within one hour after infusion. Twenty-four hours after each treatment amikacin activity is still detectable at concentrations averaging 2 to 4 mcg/g. However, the drug is not appreciably absorbed systemically following intrauterine infusion. Endometrial tissue concentrations following intramuscular injection are roughly parallel, but are typically somewhat lowerthan corresponding serum concentrations of amikacin.
AMIGLYDE-V is non-irritating to equine endometrialtissue when infused into the uterus as directed (see ADMINISTRATION AND DOSAGE). In laboratoryanimals as well as equine studies, the drug was generally found not to be irritating when injected intravenously, subcutaneously or intramuscularly.Although amikacin, like other aminoglycosides, is potentially nephrotoxic, ototoxic and neurotoxic, parenteral (intravenous) administration of AMIGLYDE-V (amikacin sulfate injection) twice daily at dosages of up to 10 mg/lb for 15 consecutive days in horses resulted in no clinical, laboratory or histopathologic evidence of toxicity.Intrauterine infusion of 2 grams of AMIGLYDE-V8 hours prior to breeding by natural service did not impair fertility in mares. Therefore, mares should not be bred for at least 8 hours following uterine infusion.
AMIGLYDE-V is indicated for the treatment of uterineinfections (endometritis, metritis and pyometra) in mares, when caused by susceptible organisms including Escherichia coli, Pseudomonas sp and Klebsiella sp. The use of AMIGLYDE-V in eliminating infections caused by the above organisms has been shown clinically to improve fertility in infected mares.While nearly all strains of Escherichia coli,Pseudomonas sp and Klebsiella sp, including those that are resistant to gentamicin, kanamycin or otheraminoglycosides, are susceptible to amikacin at levels achieved following treatment, it is recommended that the invading organism be cultured and its susceptibility demonstrated as a guide to therapy. Amikacin susceptibility discs, 30 mcg, should be used for determining in vitro susceptibility.
For treatment of uterine infections in mares, 2 grams(8 mL) of AMIGLYDE-V, mixed with 200 mL 0.9% Sodium chloride injection, USP and aseptically infused into the uterus daily for three consecutive days, has been found to be the most efficacious dosage.
There are no known contraindications for the use ofAMIGLYDE-V in horses other than a history of hypersensitivity to amikacin.
Although AMIGLYDE-V is not absorbed to an appreciableextent following intrauterine infusion, concurrent use of other aminoglycosides should be avoided because of the potential for additive effects..
No adverse reactions or other side effects have been reported.
Do not use in horses intended for human consumption.In vitro studies have demonstrated that when sperm are exposed to the preservative which is present in the 48 mLvials (250 mg/mL) sperm viability is impaired.
AMIGLYDE-V (amikacin sulfate injection) VeterinarySolution is supplied as a colorless solution which is stablewhen stored at or below 25°C (77°F). Use contents within3 months of first vial puncture.48 mL vial, 250 mg/mLStore at or below 25°C (77°F).
1. Price, K.E., et al: Microbiological Evaluation of BB-K8, a New Semisynthetic Aminoglycoside. J Antibiot 25: 709–731, 1972.2. Davies, J., Courvalin, P.: Mechanisms of Resistance to Aminoglycosides. Am J Med 62: 868–872, 1977.